Tradestie Institutional Equity Comparison Engine · Market Close Oct 02, 2026

BSLK vs VTAK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VTAK Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 4–2 Matrix Metrics)

VTAK Overall Winner 6-Pillar Tally: BSLK 1 – 2 VTAK (3 Tie) Matrix Metrics: BSLK 2 – 4 VTAK

As of Oct 02, 2026, Catheter Precision, Inc. (VTAK) is the stronger overall head-to-head candidate over Bolt Projects Holdings, Inc. (BSLK) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). BSLK carries a Unified Composite Score of 41.2/100 (SELL) at $0.58 (N/M Forward P/E, -1179.5% operating margin), whereas VTAK carries 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin).

  • Growth vs. Quality Trade-Off: VTAK earns the overall head-to-head edge with a stronger Unified Composite Score (58.1/100 HOLD vs. BSLK 41.2/100 SELL) and 0.19β · 76% Vol risk profile, whereas BSLK leads top-line expansion (+7300.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: BSLK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 19.8); meanwhile VTAK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BSLK vs VTAK
BSLK NASDAQ
Bolt Projects Holdings, Inc. Common Stock
Industrial Organic Chemicals
$0.58
-27.01% 1D
Market Cap $7.1M
TTM Revenue $3.1M
Forward P/E N/M
Beta / 30D Vol 4.04β · 148% Vol
Unified Composite Score
41.2 / 100 SELL
Tech 40.0 Fund 43.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.4%), weak momentum, RSI 20
RSI-14: 19.8 · SMA20: $1.63 · SMA50: $1.95
VTAK NYSE American Head-to-Head Winner
Catheter Precision, Inc.
Surgical & Medical Instruments & Apparatus
$0.15
-0.66% 1D
Market Cap $548,639
TTM Revenue $1.9M
Forward P/E N/M
Beta / 30D Vol 0.19β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 72.0 Fund 70.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -53.4%), weak momentum, RSI 33
RSI-14: 33.2 · SMA20: $0.16 · SMA50: $0.21

6-Pillar Scorecard Institutional Category Breakdown (BSLK 1 – 2 VTAK)

Columns: Metric · BSLK · VTAK
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E 0.1x N/M
PEG Ratio N/M N/M
EV / Revenue 4.9x 0.3x
2. Growth & Scale BSLK
Revenue Growth (YoY) +7300.0% +380.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $3.1M $1.9M
Market Cap $7.1M $548,639
3. Profitability & Quality VTAK
Gross Margin 3.2% 47.7%
Operating Margin -1179.5% -388.1%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -4288.3% -111.3%
4. Balance Sheet & Cash Flow VTAK
Cash Generation (TTM) -$5.4M -$10M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $8.2M Net Debt $4.87 Book/Sh · -111.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Specialty Chemicals Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BSLK (2) vs VTAK (4)
Institutional Metric BSLK VTAK Criterion Row Edge
Market Capitalization
Scale
$7.1M $548,639 Larger Scale Tie
Trailing P/E Ratio
Valuation
0.1x N/M Lower Multiple BSLK
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+7300.0% +380.7% Higher Growth BSLK
Operating Margin (TTM)
Profitability
-1179.5% -388.1% Higher Margin VTAK
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-4288.3% -111.3% Higher ROE VTAK
52-Week Range Position
Momentum
0% ($1–$25) 1% ($0–$3) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
4.04β · 148% Vol 0.19β · 76% Vol Lower Realized Risk VTAK
Unified Institutional Score
Composite Signal
41.2 / 100 (SELL) 58.1 / 100 (HOLD) Higher Composite VTAK
Trailing 12M Revenue (USD)
Operating Scale
$3.1M $1.9M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
3.2% 47.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 4.9x EV/Rev N/M PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$5.4M ($8.2M Net Debt) -$10M EBITDA ($4.87 Book/Sh · -111.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VTAK +69.56 pp
BSLK: -73.85% · VTAK: -4.29%
3M Horizon VTAK +62.36 pp
BSLK: -85.05% · VTAK: -22.69%
6M Horizon VTAK +62.22 pp
BSLK: -86.08% · VTAK: -23.86%
1Y Horizon VTAK +62.22 pp
BSLK: -86.08% · VTAK: -23.86%

Financial Trajectory Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)

Split-Invariant USD Revenue & Operating Margin (%)
Period BSLK Revenue VTAK Revenue BSLK Op. Margin VTAK Op. Margin Margin Leader
Q1 '25 $0M $0M -3157.9% -2416.8% VTAK
Q2 '25 $10M $0M -370.0% -1338.7% BSLK
Q3 '25 $0M $0M -1179.5% -1336.7% BSLK

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BSLK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BSLK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VTAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BSLK Moat Profile Cyclical / Execution-Driven Positioning
Specialty Chemicals Operator
Competes within the Specialty Chemicals value chain with $7.1M market capitalization and -1179.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VTAK Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $548,639 market capitalization and -388.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BSLK vs VTAK Key Questions & Quantitative Answers

As of Oct 02, 2026, Catheter Precision, Inc. (VTAK) is the stronger overall head-to-head candidate over Bolt Projects Holdings, Inc. (BSLK) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). BSLK carries a Unified Composite Score of 41.2/100 (SELL) at $0.58 (N/M Forward P/E, -1179.5% operating margin), whereas VTAK carries 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin). Growth vs. Quality Trade-Off: VTAK earns the overall head-to-head edge with a stronger Unified Composite Score (58.1/100 HOLD vs. BSLK 41.2/100 SELL) and 0.19β · 76% Vol risk profile, whereas BSLK leads top-line expansion (+7300.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BSLK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 19.8); meanwhile VTAK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BSLK leads the Growth & Scale pillar: BSLK posts +7300.0% YoY revenue growth and +0.0% YoY earnings growth on $3.1M TTM revenue (3.2% gross margin, -1179.5% operating margin), compared with VTAK at +380.7% YoY revenue growth and +0.0% YoY earnings growth on $1.9M TTM revenue (47.7% gross margin, -388.1% operating margin). Across the 3-period historical trajectory (Q1 '25 to Q3 '25), BSLK cumulative revenue shifted N/A while VTAK shifted N/A. In operating R&D and SG&A reinvestment, BSLK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VTAK.

BSLK and VTAK trade at balanced relative valuation multiples. BSLK trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported FCF margin), whereas VTAK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BSLK (-4288.3% ROE) versus VTAK (-111.3% ROE) capital efficiency.

In options market volatility and institutional positioning, BSLK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.04β · 148% Vol realized risk). By comparison, VTAK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.19β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Oct 02, 2026. For educational research only; not investment advice.